565 related articles for article (PubMed ID: 32510304)
1. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
2. Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study.
de Araujo-Souza PS; Ramanakumar AV; Candeias JM; Thomann P; Trevisan A; Franco EL; Villa LL;
BMC Infect Dis; 2014 Nov; 14():578. PubMed ID: 25730386
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
5. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women.
Wideroff L; Schiffman MH; Hoover R; Tarone RE; Nonnenmacher B; Hubbert N; Kirnbauer R; Greer CE; Lorincz AT; Manos MM; Glass AG; Scott DR; Sherman ME; Buckland J; Lowy D; Schiller J
J Infect Dis; 1996 Nov; 174(5):937-43. PubMed ID: 8896493
[TBL] [Abstract][Full Text] [Related]
7. Association of antibody to E2 protein of human papillomavirus and p16
Chuerduangphui J; Pientong C; Swangphon P; Luanratanakorn S; Sangkomkamhang U; Tungsiriwattana T; Kleebkaow P; Burassakarn A; Ekalaksananan T
Med Oncol; 2018 May; 35(6):93. PubMed ID: 29744680
[TBL] [Abstract][Full Text] [Related]
8. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
[TBL] [Abstract][Full Text] [Related]
9. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
[TBL] [Abstract][Full Text] [Related]
10. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan.
Matsumoto K; Yoshikawa H; Yasugi T; Nakagawa S; Kawana K; Takeoka A; Yaegashi N; Iwasaka T; Kanazawa K; Taketani Y; Kanda T
J Med Virol; 2003 Mar; 69(3):441-6. PubMed ID: 12526056
[TBL] [Abstract][Full Text] [Related]
11. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
12. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
[TBL] [Abstract][Full Text] [Related]
13. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
Xu Y; Wang Q; Han Y; Song G; Xu X
J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
[TBL] [Abstract][Full Text] [Related]
14. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
15. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
[TBL] [Abstract][Full Text] [Related]
16. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.
Beachler DC; Viscidi R; Sugar EA; Minkoff H; Strickler HD; Cranston RD; Wiley DJ; Jacobson LP; Weber KM; Margolick JB; Reddy S; Gillison ML; D'Souza G
Sex Transm Dis; 2015 Feb; 42(2):93-7. PubMed ID: 25585068
[TBL] [Abstract][Full Text] [Related]
18. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
[TBL] [Abstract][Full Text] [Related]
19. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.
Greenstone HL; Nieland JD; de Visser KE; De Bruijn ML; Kirnbauer R; Roden RB; Lowy DR; Kast WM; Schiller JT
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1800-5. PubMed ID: 9465097
[TBL] [Abstract][Full Text] [Related]
20. HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer.
Namvar A; Bolhassani A; Hashemi M
Bratisl Lek Listy; 2016; 117(3):179-84. PubMed ID: 26925750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]